EKF Diagnostics (LON:EKF) Announces Quarterly Earnings Results

Key Points

• EKF Diagnostics reported a quarterly earnings per share (EPS) of GBX 0.43, with a net margin of 9.37% and a return on equity of 7.03%.
• The company's stock opened at GBX 29, boasting a market capitalization of £130.24 million and a high price-to-earnings ratio of 2,101.45.
• EKF specializes in Point-of-Care analysers for Hematology and Diabetes, and offers life sciences services including the manufacture of enzymes for diagnostic applications.

EKF Diagnostics (LON:EKF - Get Free Report) issued its earnings results on Tuesday. The company reported GBX 0.43 earnings per share (EPS) for the quarter, Digital Look Earnings reports. EKF Diagnostics had a return on equity of 7.03% and a net margin of 9.37%.

EKF Diagnostics Price Performance

Shares of EKF stock remained flat at GBX 30 on Friday. The stock had a trading volume of 42,001 shares, compared to its average volume of 418,749. The stock has a market capitalization of £134.73 million, a price-to-earnings ratio of 2,173.91 and a beta of 0.57. The company's fifty day simple moving average is GBX 28.75 and its 200-day simple moving average is GBX 25.18. The company has a current ratio of 4.60, a quick ratio of 1.77 and a debt-to-equity ratio of 0.34. EKF Diagnostics has a fifty-two week low of GBX 18.40 and a fifty-two week high of GBX 32.

EKF Diagnostics Company Profile

EKF is an AIM-listed global diagnostics business focussed on: ● Point-of-Care analysers in the key areas of Hematology and Diabetes ● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications. EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.